Skip to content
Screener

Nuvation Bio NUVB Q2 2026 earnings

Reported August 6, 2026 · Before market open

Revenue$31.7MBeat by $4.7M
EPS-$0.15Miss by $0.01
Revenue estimate$27.0M
EPS estimate-$0.14

Next report

Nov 2, 2026 (in a month)
Revenue estimate$35.3M
EPS estimate-$0.12

Financials

Q2 2026

Income statement

See full
Revenue$31.7M+556%
Operating income-$51.0M+19.7%
Net income-$62.8M-6.5%
EPS (diluted)-$0.18-5.9%

Balance sheet

See full
Cash & equivalents$258.6M+4.3%
Total debt$9.5M-83.5%
Total equity$253.9M-31.9%
Total assets$744.5M+15.0%

Cash flow

See full
Operating cash flow-$43.0M+10.8%
CapEx$254.0K+40.3%
Free cash flow-$43.2M+10.6%

Valuation & ratios

Valuation

as of 09/18/26
See full
Market cap$2.13B+96.4%
Enterprise value$1.88B+110%
P/S12.5×-63.0×

Profitability

See full
Operating margin-81%-39.4pp
Net margin-88.2%-42.7pp
FCF margin-75.7%-36.6pp

Returns & leverage

See full
Return on equity-47.8%-9.8pp
Debt / equity0×-0.1×
Current ratio8.4×-1.0×

Segments

By product

See full
Product Revenue$23.2M+2,800%
License$8.5M+136%
Research And Development Service Revenue$2.0M-9.1%
Royalty Revenue$1.6M+700%

FAQ

When did Nuvation Bio report Q2 2026 earnings?
Nuvation Bio (NUVB) reported Q2 2026 earnings on August 6, 2026 before market open.
What were Nuvation Bio's Q2 2026 revenue and EPS?
Nuvation Bio reported revenue of $31.7M and eps of $-0.15 for Q2 2026.
Did Nuvation Bio beat estimates in Q2 2026?
Revenue beat the consensus estimate of $27.0M by $4.7M. EPS missed the consensus estimate of $-0.14 by $0.01.
How did Nuvation Bio's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 555.6% from $4.8M a year earlier and eps grew 11.8% from $-0.17.
Where can I find Nuvation Bio's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-336751) and the 10-Q periodic report (0001193125-26-336646) directly on SEC EDGAR. The filing index links above go to sec.gov.